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Background: Several studies have shown the antibacterial effectiveness of 0.2% chlorhexidine (CHX) in both in vitro
and in vivo studies. In this way, CHX comes directly in contact with saliva. This in vitro study aimed at investigating
the possible neutralizing effect of saliva on CHX.
Methods: Saliva samples (12 ml) were collected from twenty healthy volunteers. The aerobic and anaerobic
bacterial counts in saliva were determined on Colombia blood agar (CBA) and yeast cysteine agar (HCB),
respectively. Saliva from each subject was divided among 4 experimental groups (3 ml/group). Samples were
centrifuged at 4000 g for 10 min. The centrifuged salivary bacteria were incubated with the following solutions:
0.2% CHX in saliva, CHX in saliva with 7% ethanol, CHX in 0.9% NaCl, CHX in 0.9% NaCl with 7% ethanol. After
exposure for 1 min or 3 min to these CHX solutions, the CHX was neutralized and the bacteria were cultivated,
after which the number of colony forming units (aerobic and anaerobic) was determined.
Results: CHX reduced the CFU in all groups significantly (p = 0.0001). Therefore, CHX had a similar effect on both
aerobic and anaerobic microorganisms. Significantly more bacteria survived the effect of CHX when kept in salivary
solution. This effect from saliva could be compensated by the addition of ethanol. In the absence of saliva there
was no significant difference observed in the effectiveness of CHX with respect to ethanol. Prolonging the exposure
time to 3 min enhanced the effectiveness of CHX.
Conclusions: The effect of saliva on the antimicrobial activity of CHX was weak albeit statistically significant.
However, addition of 7% ethanol compensates this effect. The impact of saliva on the reduction of the
antimicrobial efficacy of mouthrinses such as CHX needs to be taken into consideration with regard to improving
their antibacterial properties.
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Chlorhexidine digluconate (CHX) is a cationic biguanide
which is bacteriostatic in low and bactericidal in higher
concentrations [1]. It is more effective in alkaline than in
acidic solution [2]. In addition to pH value, the antimicro-
bial activity of CHX is affected by the environment, i.e. by
the presence of organic substances and food compounds,
respectively, which reduce CHX activity [3]. CHX has
demonstrated antibacterial activity on the salivary flora, as
well as on the development of oral biofilms [4-6], but may* Correspondence: ali.al-ahmad@uniklinik-freiburg.de
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unless otherwise stated.be ineffective against biofilms which are already adherent
or mature [7]. CHX at a concentration of 0.2% is regarded
as the gold standard in the reduction of plaque formation
and as a local antibacterial compound [8,9]. Because of
this, different forms of CHX are commonly used in dentis-
try. They can be found as varnishes in dental fissures to
prolong CHX release in the oral cavity [8,10], and as
CHX-chips for local antibacterial therapy of periodontal
pockets [11]. Furthermore, CHX as a gel, spray, or mouth-
wash has been described as an effective adjuvant to mech-
anical plaque control, especially during periodontal
therapy [8,12,13]. Although the clinical use of CHX is
well-documented, conflicting results indicate that its
effectiveness might be influenced by a number of factors,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion and concentration [14]. Moreover, CHX comes in
direct contact with the saliva which as a complex fluid con-
tains numerous proteins and other ionic compounds able
to bind to CHX, possibly resulting in its neutralization and
subsequently in the selection of salivary bacteria. Portenier
et al. demonstrated the inactivation of CHX by contact
with the organic components of dentin and bovine serum
albumin, respectively in an in vitro study [15]. However, in
this study CHX diacetate and not digluconate was exam-
ined. CHX affects bacterial metabolic activity by interacting
with the cellular membrane [16]. Due to its cationic nature,
CHX binds to the phosphate groups in lipopolysaccharides
(anionic compounds) in the bacterial cell wall, thereby
interfering with membrane transport. As a result, leakage
of low molecular weight molecules occurs [17]. Many
studies have detected powerful antimicrobial action in the
oral cavity, but there have been few investigations on the
probable inactivation of CHX by the components of
human saliva to date [3,18].
The present study clearly draws attention to a probable
inactivating effect of saliva on CHX. To investigate the
efficacy of CHX in vitro, CHX neutralizers are necessary
to stop the antimicrobial activity [19]. These neutralizers
also contain complex mixtures of proteins such as the
protease peptone [20,21]. The working hypothesis of the
present study was that human saliva, a fluid rich in
proteins and ionic compounds, has a neutralizing effect




Stimulated human saliva (HS) from 20 volunteers was
tested. The subjects were enrolled in the study only if
the following criteria were met: no pregnancy, no drug
treatment, no antibiotic therapy within the previous
3 months, and no use of mouth rinses two weeks before
collection of saliva. The patients were between 23 and
49 years of age. Dental examination was carried out by
an experienced dentist. There were no signs of open
carious lesions or of periodontitis. The plaque index was
close to zero. Stimulated saliva was collected by chewing
paraffin 2 h after breakfast followed by brushing teeth
with a particular commercial toothpaste product. In-
formed consent was taken from all volunteers to partici-
pate in this study.
Study design and treatment of salivary bacteria
The pH of each salivary sample was measured using a
pH meter (inoLab pH 720, WTW, Weilheim, Germany)
and was in the range of 6.9-7.4. The aerobic and anaerobic
bacterial load of the fresh saliva was determined as a base-
line. Directly after collection saliva (12 ml) from eachvolunteer was divided among four experimental groups
(3 ml/group). Samples were centrifuged at 4000 g for
10 min (Hettich, Tuttlingen, Germany). The resulting
supernatants in group A and B were decanted into sterile
cups and used to prepare 0.2% Chlorhexidine digluconate
(CHX, Fagron, Barsbüttel, Germany) by diluting a 20%
CHX stock solution. The supernatants in groups C and D
were replaced by the same volume of saline solution.
Salivary bacteria obtained by centrifugation were treated
in every group as follows: group A: 0.2% CHX in saliva
supernatants without 7% alcohol, group B: 0.2% CHX in
saliva supernatants with 7% ethanol, group C: 0.2% CHX
in saline solution without 7% ethanol and group D: 0.2%
CHX in saline solution with 7% ethanol. The antibacterial
activity of CHX was evaluated after 1 min and 3 min.
CHX was deactivated by adding CHX-neutralizer after
1 min or 3 min as described below.
Neutralization of chlorhexidine digluconate (CHX)
The effectiveness of CHX after 1 min and 3 min was
investigated using the CHX (Fagron, Barsbüttel, Germany)
neutralizers as modified after Sheikh [21]. Briefly, there
were two methods of neutralization used: Neutralizer
No.1 consists of 3% asolectin (Fluka, Sigma-Aldrich
Chemie GmbH, Steinheim, Germany), 10% Tween 80
(Tween® 80, Sigma-Aldrich Chemie GmbH, Steinheim,
Germany), 0.3% sodium thiosulfate (Dr. Köhler Chemie
GmbH, Alsbach-Hähnlein, Germany) in 0.1% aqueous
proteose peptone (Becton Dickinson, New Jersey, USA).
One ml of this neutralizer was added to 100 μl of the
treated bacteria. Neutralizer No.2 is composed of 0.3%
asolectin, 1% Tween 80, 0.3% sodium thiosulfate in 1%
Tween 80. Neutralizer No. 2 (100 μl) was applied on the
agar plates.
Determination of the colony forming units (CFU)
The colony-forming units (CFUs) of both the collected
saliva and of the different samples were evaluated quanti-
tatively. For colony counting, dilutions (10−1-10−5) were
prepared in 0.9% NaCl solution, 100 μl each of the differ-
ent dilutions were plated onto yeast-cysteine blood agar
(HCB) to cultivate anaerobic microorganisms at 37°C for
7 d (anaerobic jar, Anaerocult A; Merck, Darmstadt,
Germany). Columbia blood agar (CBA) plates were used
to cultivate aerobic and facultative anaerobic microorgan-
isms after incubation at 37°C under a 5% CO2 atmosphere
for 3 d.
Statistical analysis
For aerobic and anaerobic cultivation a linear mixed
model was fitted [22]. The response variable was the
logarithm of the number of CFU. It was modelled as a
linear function of time (1 min and 3 min), with group
and the time-group interaction as explanatory variables.
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account, the proband was fitted as a random effect. Vari-
ance components were used as a covariance structure.
Model assumptions were evaluated graphically by resid-
uals and other regression diagnostics including Cook's
distance to indicate data points that are particularly worth
checking for validity. Normality of the error terms was as-
sumed. Least-square means were calculated with 95% CI
and graphically displayed. Pairwise differences of least-
square means were calculated and p-values were ad-
justed by the method of Tukey-Kramer to address the
multiple test problem for pairwise comparisons [23].
All calculations were performed with the statistical soft-
ware SAS system version 9.1.3 using the PROC MIXED
procedure.
Results
The numbers of colony forming units (CFUs) in every
group were calculated after 1 min and 3 min of treatment
with 0.2% CHX, and statistically compared to the CFU
number from untreated saliva (baseline). The results of
aerobic and anaerobic CFUs grown after treatment of sal-
ivary bacteria are shown in Figures 1 and 2. In all groups
the baseline bacterial count was reduced significantly by
0.2% CHX (p = 0.0001). No significant differences of CHX
effects were observed when comparing aerobic and anaer-
obic bacteria. In comparison to the baseline bacterial load
of fresh saliva, the aerobic CFUs were significantly less re-
duced after 1 min of action of CHX in salivary supernatant*
*
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Figure 1 Boxplots depicting bacterial count for surviving aerobic colo
treatments with 0.2% CHX digluconate in the different groups: centri
centrifuged bacteria and 0.2% CHX in saliva with ethanol, centrifuged
bacteria and 0.2% CHX in NaCl with ethanol. The medians and whisker
maximum values. n = 20, *p≤ 0.01 (Tukey-Kramer). The statistical significanc
the tested groups and the baseline.(group A, p = 0.0005, median 4.78). However, in this group
the efficacy of CHX was significantly lower than that of
CHX and 7% ethanol (group B, p = 0.0007, median 4.27),
or CHX in 0.9% NaCl (group C, p = 0.009, median 4.47),
or of CHX in 0.9% NaCl and 7% ethanol (group D,
p = 0.0001, median 3.6). No statistical difference was
found with regard to the effectiveness of CHX in groups
B, C, and D. Furthermore, the anaerobic bacterial count
was significantly reduced after 1 min of treatment as com-
pared to the baseline (p = 0.0001). The four suspensions
examined showed a comparable tendency for sheltering
lower numbers of anaerobic microorganisms. Therefore,
CHX in salivary supernatant (group A, p ≤ 0.001, median
4.74), CHX and 7% ethanol (group B, p ≤ 0.001, median
4.25), CHX in 0.9% NaCl (group C, p ≤ 0.001, median 4.33)
and CHX in 0.9% NaCl and 7% ethanol (group D,
p = 0.0001, median 3.87) presented significantly lower
bacterial counts compared to the baseline.
Aerobic salivary bacteria were significantly reduced after
3 min of incubation in 0.2% CHX in all of the groups
compared with the baseline level (median of baseline
value 8.24, p = 0.0007). However, no significant difference
in the effect of CHX was observed in saliva with or
without 7% ethanol after 3 min. After 3 minutes, the effect
of CHX in 0.9% NaCl solution (group C, p ≤ 0.001, median
3.42) was significantly more pronounced than in saliva
(group A, p ≤ 0.001, median 3.78). There was no difference
in the antibacterial effectiveness of CHX in groups C and
D after 3 min (p ≥ 0.05).*
ary bacteria
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bacteria and 0.2% CHX in NaCl without ethanol, centrifuged
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Figure 2 Boxplots depicting the bacterial count of surviving anaerobic colony forming units (CFUs) determined after 1 min and 3 min
treatments with 0.2% CHX digluconate in the different groups: centrifuged bacteria and 0.2% CHX in saliva without ethanol,
centrifuged bacteria and 0.2% CHX in saliva with ethanol, centrifuged bacteria and 0.2% CHX in NaCl without ethanol, centrifuged
bacteria and 0.2% CHX in NaCl with ethanol. The medians and whiskers are displayed. The whiskers depict the range between minimum and
maximum values. n = 20, *p≤ 0.01 (Tukey-Kramer). The statistical significance regarding the bacterial counts was high (p ≤ 0.001) between each of
the tested groups and the baseline.
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tested suspensions allowed for a similar (p ≥ 0.05) level
of microbial colonization after 3 min. However, the an-
aerobic CFU after 3 min of treatment with the above-
mentioned suspensions were significantly reduced when
compared to the baseline (median of baseline value 8.62,
p = 0.0007).
Discussion
The present study aimed to investigate possible neutraliz-
ing effects on chlorhexidine gluconate (CHX) by human
saliva in vitro. Since CHX is a strongly cationic molecule
it can react with anionic chemicals, resulting in inactiva-
tion of antimicrobial activity. The pH of unstimulated
saliva ranges between 5.8 and 7.1, with an average daily
flow between 1 and 1.5 l in healthy individuals [24,25].
Portenier et al. [26] showed that the presence of dentine
or bovine serum albumin caused a marked delay in the
antibacterial effect of CHX. These results support the re-
sults of the present study. This may increase the resistance
of some oral bacteria against its antibacterial action. Such
presumptions were also made by Veksler et al. [27] with
regard to deactivation of CHX by high organic load. The
authors discussed the effect of pre-procedural rinsing with
0.12% CHX on aerobic oral bacterial strains during scaling
and root planning procedures. They investigated possible
inactivation of CHX by blood and debris arising from
scaling and root planing, and found that CHX was not
inactivated by this high organic load. In contrast, Lampeet al. [28] found that the antimicrobial activity of a gel
containing 0.0156% CHX was decreased by human blood
when tested against Chlamydia trachomatis in vitro. How-
ever, an influence of saliva on CHX with regard to bacterial
reduction cannot be studied in vivo, since entry of bacteria
from the tongue, mucosa and other parts of the oral cavity
cannot be excluded. Therefore, an in vitro approach was
chosen to study survival of oral bacteria after exposure to a
clinically relevant concentration of CHX. For studies such
as this it is important to stop the incubation of bacteria
with CHX through effective deactivation of the residual
antimicrobial activity of CHX. For this purpose a neutralis-
ing agent should be used which is itself not toxic to the
tested bacteria. The protein-rich neutralizers which were
used in this study have been reported as being non-toxic
and effective in the deactivation of the antibacterial proper-
ties of CHX [20,21]. The remaining cultivated bacteria can
be considered as beingselected due to salivary components.
Herrera et al. [19] suggested resistance of some bacterial
species such as Peptostreptococcus micros, Capnocyto-
phaga sputigena and Actinomyces naeslundii against
CHX. This resistance was shown in the absence of ethanol
in vitro. The authors considered the absence of ethanol to
be a reason for the observed resistance against CHX. Our
results are in agreement with the study of Herrera et al.
[19]. Furthermore, the present data indicated that saliva
reduces the antibacterial activity of CHX and could be
considered a reason for increased resistance of some oral
bacteria against CHX. Many studies investigated the
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after periodontal treatment [29-31]. In these studies, CHX
(0.2%) was investigated as the most frequently used con-
centration in dentistry. To date, the influence of CHX on
salivary bacteria was studied in combination with testing
of the antibacterial effects of CHX in the oral cavity
[19,32-34]. These studies aimed to investigate the ef-
fectiveness of different formulation of mouth rinses
containing CHX. This issue is of practical relevance,
but does not give information about the actual impact
of human saliva on the antibacterial activity of CHX.
However, entry of oral bacteria from parts of the oral
cavity which were not in contact with CHX after rinsing
could give false positive results with respect to resistance
of oral bacteria in saliva. In the present study only salivary
bacteria already exposed to the antibacterial activity of
CHX in saliva or in physiological NaCl solution without
ethanol or together with ethanol were isolated. This can
give insight into the actual survival and resistance of
salivary bacteria with or without the presence of human
saliva, which can interact with CHX.
An inactivation of CHX by saliva has been investigated
in vitro by Spijkervet et al. [3]. The authors dissolved
CHX in human saliva and studied the minimum bacteri-
cidal concentrations (MICs) of CHX for different isolates
of indigenous flora and for hospital-acquired microorgan-
isms. The resulting MICs revealed a decreasing effect of
human saliva on the antibacterial activity of CHX against
hospital-acquired bacteria. The authors concluded that
mouth rinsing with CHX is of limited value for decontam-
ination of the oral cavity. However, in our study the total
bacterial load of human saliva was exposed to CHX. There
are no in vitro investigations on the influence of saliva on
the antibacterial activity of CHX against highly diverse
oral bacteria. This would not only detect a selection
process for bacteria isolated from caries lesions, but might
also give evidence about alteration of the physiological
flora, which subsequently should be studied in more detail
to identify which specific bacteria survive the effects of
CHX in the presence and absence of human saliva.
The presence of ethanol in mouth rinse formulations is
controversial. Some studies have hypothesized an increase
in the risk of oral cancer [35]. However, some studies have
suggested that the carcinogenic effect of ethanol only oc-
curs if concentrations above 25% are used frequently [36].
Another study found no association of oral cancer with
mouthwashes containing ethanol [37]. The present data
have demonstrated a significant increase in antibacterial
activity after mixing 0.2% CHX with 7% ethanol in saliva.
This is in agreement with the suggestions of Herrera et al.
[19]. This synergism could be caused by additional anti-
microbial effects due to the 7% ethanol itself as well as its
impact on salivary proteins. This could possibly compen-
sate the neutralizing effects of these proteins.Accordingly, human saliva can inactivate the antibacterial
activity of CHX against some oral bacteria to some extent,
inducing selective processes in the bacterial populations of
human saliva. However, the effect of saliva on the anti-
microbial activity of CHX was weak albeit statistically
significant. These processes should be studied by cultivation
and classification of selected bacteria in vitro. Furthermore,
the well-known enhancing effect of ethanol on the antibac-
terial activity of CHX was confirmed.
Conclusions
Human saliva has a neutralizing effect on chlorhexidine
(CHX). The addition of 7% ethanol can compensate this
effect.
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